Pick two compounds to see them side by side: what type of compound each is, its half-life, how far it got in clinical trials, its WADA status, how much it lowered testosterone in studies, its liver signal, the strength of the evidence and the side effects studies reported. Every cell comes from the Sarmguide database and links to its source.
| SR9009 | Cardarine | |
|---|---|---|
| Type | Other | Other |
| Class | REV-ERB agonist (body-clock and metabolic modulator) | PPARδ agonist (metabolic modulator) |
| Half-life | Not established | Not established |
| Research stage | Preclinical source | Phase 2 source |
| Human studies | 0 | 4 |
| Approved as a medicine | No | No |
| WADA (sport) | Prohibited at all times source | Prohibited at all times source |
| Testosterone suppression | Not measured Not established. SR9009 is not a hormone and does not act on the androgen receptor. No study has measured testosterone with it. source | Not measured Cardarine is not a hormone and does not act on the androgen receptor. The published human trials did not report testosterone, so there are no human data either way. source |
| Liver signal | Moderate | Mild |
| Strength of evidence | Very limited | Moderate |
| Side effects reported | ||
| Markers studies tracked | ALT/AST (liver enzymes), Bilirubin, INR (blood clotting) | Lipid panel (HDL, LDL, triglycerides), ALT/AST (liver enzymes), Fasting glucose and insulin, CK (creatine kinase) |
Where to buy (affiliate links)
Sarmguide is reader-supported. We may earn a commission from partner links. How we earn These listings are separate from the research above: they are the same whatever the result shows and are not a recommendation.
How the comparison works
Each row is read from the compound’s database record, the same data that powers its fact sheet. A small source marker next to a value links to the study or document behind it. “Not established” means we found no reliable human data, not that the risk is zero.
The suppression, liver and evidence rows are Sarmguide scores from 0 to 3, based on the cited studies; suppression is marked “human data” or “animal data”, and “Not measured” when there are no data. The side-effects row lists up to six findings with their evidence label (trial, case report, animal and so on), so a trial finding and a single case report never look the same.
After the table, a separate section headed “Where to buy (affiliate links)” shows the partner shop’s listings for the two compounds. It is the same whatever the table shows and is not a recommendation.
You can share a comparison: the page address keeps your choice, for example ostarine vs LGD-4033 or MK-677 vs tesamorelin.
What a side-by-side table cannot show
- It lines up separate studies; it is not a head-to-head trial. Studies differ in dose, length and who took part (older adults, cancer patients, young men), so numbers in two columns are not directly comparable.
- Half-lives come from different study designs. RAD-140’s figure (about 45 hours) comes from a trial in women with advanced breast cancer (LoRusso 2022); LGD-4033’s (24 to 36 hours) from healthy young men (Basaria 2013).
- It does not cover combinations. For that, use the stack checker.
Written comparisons
For the most searched pairs we have full articles with the studies, the side effects and the reader reports in context:
- RAD-140 vs LGD-4033
- Ostarine vs RAD-140
- Ostarine vs LGD-4033 (ligandrol)
- Cardarine vs ostarine
- Andarine (S4) vs ostarine
- YK-11 vs RAD-140 and YK-11 vs LGD-4033
- RAD-140 vs RAD-150
- SR9009 vs cardarine
- MK-677 vs HGH
- CJC-1295 vs ipamorelin
- SARMs vs steroids, SARMs vs testosterone, SARMs vs TRT, SARMs vs prohormones and SARMs vs peptides